Cytek Biosciences announced that a jury in the U.S. District Court for the District of Delaware returned a verdict in a patent infringement lawsuit brought by Beckman Coulter, Inc. The jury found Cytek not liable on three of four claims, ruling noninfringement and invalidity. On the fourth claim, the jury found no literal infringement but ruled infringement under the doctrine of equivalents, awarding $20 million in lost profits and $36.11 million in royalties for past damages. Cytek intends to challenge this finding through post-verdict motions and potentially an appeal to the Federal Circuit. The verdict does not require changes to current product offerings or operations. Cytek Biosciences is a leading cell analysis solutions company that develops high-resolution flow cytometry instruments and reagents.

Cytek Biosciences reported second quarter 2026 financial results with total revenue of $48.1 million, a 6% increase year-over-year. The company updated its full-year 2026 revenue guidance to $207 million–$212 million, raising the midpoint by $1 million. GAAP net loss widened to $12.2 million from $5.6 million in the prior year period, driven by a $1.6 million write-off of an investment and increased litigation-related expenses within general and administrative costs. Operating expenses rose 15% to $39.7 million. The company launched the Cytek Borealis flow cytometer and expanded its installed base to 3,933 instruments. Cytek Biosciences operates in the life sciences industry, providing cell analysis solutions including flow cytometers, reagents, and software.

Cytek Biosciences, Inc. entered into a severance agreement with former Chief Legal Officer and Corporate Secretary Valerie Barnett following her termination on June 29, 2026. The agreement includes a one-time lump sum severance payment of $365,775.12 and COBRA premium coverage, with enhanced benefits if a Change in Control occurs within three months of her separation. Ms. Barnett will also provide transition support services via a consulting agreement effective July 10, 2026, at a rate of $1,000 per hour. Cytek Biosciences, Inc. is a life sciences company providing flow cytometry technology solutions.

Valerie Barnett will depart from her role as Chief Legal Officer and Corporate Secretary of Cytek Biosciences, Inc., effective June 29, 2026. The company stated that her separation is not due to any disagreements regarding operations, policies, or practices. Cytek Biosciences, Inc. is a life sciences company that develops flow cytometry technologies.